Approfondimenti generali
American Society of Clinical Oncology (ASCO) Breast Cancer Guidelines [Apri]
Neoplasie della mammella, Linee Guida AIOM, 2017 [Apri]
ESMO Clinical Practice Guidelines: Breast Cancer [Apri] A service of the U.S. National Institutes of Health [Apri]
Referenze bibliografiche specifiche
Witkiewicz AK, et al. CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes Cancer 2014;5:261–272 [Apri]
Finn RS, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77 [Apri]
Ma CX, et al. Mechanisms of aromatase inhibitor resistance.Nat Rev Cancer 2015;15:261-275 [Apri]
Kroman N et al. Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 2000;320:474-478. [Apri]
Akarolo-Anthony S et al. Emerging breast cancer epidemic: evidence from Africa. Breast Cancer Res 2010;12:S8 [Apri]